A Study of JNJ-64304500 in Participants With Alopecia Areata

Janssen Research & Development, LLC

Overview

The purpose of this study is to evaluate the clinical response of 22 weeks of study intervention with JNJ-64304500, compared with placebo, in participants with moderate to severe alopecia areata (AA).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Alopecia Areata

Interventions

JNJ-64304500DRUG

JNJ-64304500 injection will be administered subcutaneously.

PlaceboDRUG

Matching placebo injection will be administered subcutaneously.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Participant has a physician confirmed diagnosis of moderate to severe Alopecia Areata (AA) (greater than or equal to \[\>=\] 50 percent \[%\] scalp involvement) as measured using the severity of Alopecia tool (SALT) score; or participant has \>=95% loss of scalp hair for enrollment as alopecia totalis (AT) or alopecia universalis (AU) subtypes at the time of screening and baseline * Current episode of hair loss is greater than (\>) 6 months (without evidence of spontaneous terminal hair regrowth within 6 months at the time of screening and baseline), but less than or equal to (\<=8) years * Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at either screening or Week 0. Any abnormalities, must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator * Medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel or hematology are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator Key Exclusion Criteria: * History of liver or renal insufficiency (estimated creatinine clearance below 60 milliliters per minute (mL/min)); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine (except stable thyroid diseases), neurologic, hematologic, rheumatologic, psychiatric disorders, or metabolic disturbances * Currently has a malignancy or has a history of malignancy (with the exceptions of participants having adequately treated and cured basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ occurring more than 5 years prior to randomization) * Known allergies, hypersensitivity, or intolerance to JNJ-64304500 or its excipients * Participants with current episode of hair loss for \>8 years * Has previous treatment with an oral janus kinase (JAK) inhibitor

Locations (22)

Forcare Clinical Research, Inc.

Tampa, Florida, United States

Outcomes

Primary Outcomes

Percentage of Participants Achieving a Severity of Alopecia Tool (SALT)90 Response

The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of scalp surface area (SSA) in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent (%) of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss). SALT90 is defined as 90% or more regrowth compared with baseline.

Time frame: Week 24

Secondary Outcomes

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Number of participants with TEAEs will be reported. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Time frame: Up to Weeks 24 and 38

Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)

Number of participants with treatment-emergent SAEs will be reported. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame: Up to Weeks 24 and 38

Number of Participants With Adverse Events Leading to Discontinuation of Study Intervention

Number of participants with AEs leading to discontinuation of study will be reported.

Time frame: Up to Weeks 24 and 38

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Indiana Clinical Trial Center

Plainfield, Indiana, United States

Dermatology Specialists

Louisville, Kentucky, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Columbia University Medical Center

New York, New York, United States

Oregon Dermatology and Research Center

Portland, Oregon, United States

University of Pittsburgh Department of Dermatology

Pittsburgh, Pennsylvania, United States

Modern Research Associates

Dallas, Texas, United States

Center for Clinical Studies

Webster, Texas, United States

Sinclair Dermatology

East Melbourne, Australia

...and 12 more locations

Number of Participants With Adverse Events Reasonably Related to Study Intervention

Number of participants with AEs reasonably related to study intervention will be reported.

Time frame: Up to Weeks 24 and 38

Number of Participants With Adverse Events of Injection-Site Reactions

Number of participants with AEs of injection-site reactions will be reported. An injection-site reaction is any AE at a subcutaneous (SC) study intervention injection-site.

Time frame: Up to Weeks 24 and 38

Number of Participants with Adverse Events of Infections

Number of participants with AEs of infections, including serious infections (including reactivation of latent infections) and infections requiring oral or parenteral antimicrobial treatment will be reported.

Time frame: Up to Weeks 24 and 38

Number of Participants With Clinically Significant Abnormalities in Vital Signs

Number of participants with clinically significant abnormalities in vital signs including pulse rate, respiratory rate and blood pressure will be reported.

Time frame: Up to Weeks 24 and 38

Number of Participants With Clinically Significant Abnormalities in Laboratory Tests

Number of participants with clinically significant abnormalities in laboratory tests including hematology and chemistry will be reported.

Time frame: Up to Weeks 24 and 38

Percentage of Participants Achieving SALT50 Response

Percentage of participants achieving SALT50 response will be reported. The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of SSA in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss). SALT50 is defined as 50% or more regrowth from baseline.

Time frame: Week 24

Percentage of Participants Achieving SALT75 Response

Percentage of participants achieving SALT75 response will be reported. The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of SSA in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss). SALT75 is defined as 75% or more regrowth from baseline.

Time frame: Week 24

Change From Baseline in SALT Score at Week 24

Change from baseline in SALT score at Week 24 will be reported. The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of SSA in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss).

Time frame: Baseline and Week 24

Percent Change in SALT Score from Baseline at Week 24

Percent change from baseline in SALT score at Week 24 will be reported. The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of SSA in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss).

Time frame: Baseline and Week 24

Percentage of Participants Achieving SALT Score Less Than or Equal to (<=) 10

Percentage of participants with SALT score \<=10 will be reported. The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of SSA in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss).

Time frame: Week 24

Percentage of Participants Achieving SALT Score <=20

Percentage of participants with SALT score \<=20 will be reported. The SALT score is a global severity score that captures percentage of hair loss by dividing the scalp into 4 quadrants (left side, right side, top and back quadrant) with assigned percent of SSA in each quadrant. After indicating the percent of loss per quadrant the value is multiplied by the percent of hair for each section (18% sides, 40% top, and 24% back) and the values are summed to generate the total percentage of scalp hair loss or SALT score. The range in score is from 0-100 reflecting the percent hair loss on the scalp (0=no hair loss and 100= total hair loss).

Time frame: Week 24